{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:24Z","timestamp":1781639724676,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Juntendo Research Branding Project, Health, Labor and Welfare Sciences Research Grants","award":["22GB1002"],"award-info":[{"award-number":["22GB1002"]}]},{"name":"Japan Society for the Promotion of Science under Grants-in-Aid for Scientific Research","award":["20K09355, 20K09398, and 24K10497"],"award-info":[{"award-number":["20K09355, 20K09398, and 24K10497"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic normal pressure hydrocephalus (iNPH) overlaps clinically and pathologically with Alzheimer\u2019s disease (AD), making differential diagnosis and prognostication challenging. The identification of reliable and minimally invasive plasma biomarkers would have major clinical implications for distinguishing iNPH from AD and for monitoring disease course and surgical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted three studies: (Study 1) cross\u2011sectional comparisons of plasma phosphorylated tau 217 (p\u2011Tau217) and amyloid-\u03b2 oligomers (A\u03b2O) among healthy controls (HCs;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), iNPH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200976), and AD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) groups, accompanied by receiver operating characteristic (ROC) analysis; (Study 2) correlation analyses within preoperative iNPH group to assess associations between biomarkers and clinical indices, as well as two\u2011group comparisons between iNPH group with and without AD pathology stratified by CSF p\u2011Tau181\u2009&gt;\u200930 pg\/mL; and (Study 3) longitudinal pre- and postoperative assessments following shunt surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the three\u2011group analyses, plasma p\u2011Tau217 effectively discriminated iNPH from AD (AUC\u2009=\u20090.79, 95% = CI 0.700\u20130.882), whereas discrimination between HCs and iNPH was poor (AUC\u2009=\u20090.48). Plasma A\u03b2O moderately discriminated HCs from iNPH (AUC\u2009=\u20090.71, 95% CI\u2009=\u20090.567\u20130.848). In the preoperative iNPH group, CSF and plasma p\u2011Tau217 showed a strong correlation (\u03c1\u2009=\u20090.736,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas CSF and plasma A\u03b2O showed no significant correlation (\u03c1 = \u22120.047,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.689). Among iNPH group with AD pathology (CSF p-Tau181\u2009&gt;\u200930 pg\/mL), plasma p-Tau217 was higher, plasma A\u03b2O was lower, and Frontal Assessment Battery (FAB) scores were reduced compared with those without AD pathology. For detecting coexistent AD pathology in iNPH group, AUCs were modest for plasma p\u2011Tau217 (0.64), A\u03b2O (0.63), and p\u2011Tau217\/A\u03b2O ratio (0.66). Postoperatively, iNPH grading scale (GS), Mini-Mental State Examination (MMSE), and FAB scores improved significantly; CSF and plasma A\u03b2O levels decreased, CSF p\u2011Tau217 increased, whereas plasma p\u2011Tau217 levels remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma p-Tau217, reflecting AD-related pathology, and plasm A\u03b2O, reflecting disease stage, provide complementary information for distinguishing iNPH from AD, assessing comorbidity of AD pathology in iNPH and evaluating postoperative changes. Their combined measurement may support differential diagnosis, aid the preoperative identification of concomitant AD pathology in iNPH, and serve as a minimally invasive screening and triage tool as well as a means of postoperative monitoring, while acknowledging that discrimination between HCs and iNPH at individual level remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-026-00784-8","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:45:58Z","timestamp":1772721958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma p-Tau217 and amyloid-\u03b2 oligomers as complementary biomarkers for differential diagnosis, comorbidity detection and disease monitoring in idiopathic normal pressure hydrocephalus"],"prefix":"10.1186","volume":"23","author":[{"given":"Ko","family":"Horikoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kamohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Tsunemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostadin","family":"Karagiozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"2","key":"784_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2176\/nmc.st.2020-0292","volume":"61","author":"M Nakajima","year":"2021","unstructured":"Nakajima M, Yamada S, Miyajima M, et al. Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo). 2021;61(2):63\u201397. https:\/\/doi.org\/10.2176\/nmc.st.2020-0292.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"22","key":"784_CR2","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1056\/NEJMoa2503109","volume":"393","author":"MG Luciano","year":"2025","unstructured":"Luciano MG, Williams MA, Hamilton MG, et al. A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus. N Engl J Med. 2025;393(22):2198\u2013209. https:\/\/doi.org\/10.1056\/NEJMoa2503109.","journal-title":"N Engl J Med"},{"issue":"5","key":"784_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jalz.2010.12.008","volume":"7","author":"D Cabral","year":"2011","unstructured":"Cabral D, Beach TG, Vedders L, et al. Frequency of Alzheimer\u2019s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. Alzheimers Dement. 2011;7(5):509\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2010.12.008.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"784_CR4","doi-asserted-by":"publisher","first-page":"22744","DOI":"10.1038\/s41598-024-72559-w","volume":"14","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cao C, Li M, He H, Luo L, Guo Y. Association between idiopathic normal pressure hydrocephalus and Alzheimer\u2019s disease: a bidirectional Mendelian randomization study. Sci Rep. 2024;14(1):22744. https:\/\/doi.org\/10.1038\/s41598-024-72559-w. Published 2024 Sep 30.","journal-title":"Sci Rep"},{"issue":"1","key":"784_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12987-017-0062-5","volume":"14","author":"Z Chen","year":"2017","unstructured":"Chen Z, Liu C, Zhang J, Relkin N, Xing Y, Li Y. Cerebrospinal fluid A\u03b242, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Fluids Barriers CNS. 2017;14(1):13. https:\/\/doi.org\/10.1186\/s12987-017-0062-5. Published 2017 May 10.","journal-title":"Fluids Barriers CNS"},{"issue":"12","key":"784_CR6","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/diagnostics12122976","volume":"12","author":"ES Pyrgelis","year":"2022","unstructured":"Pyrgelis ES, Boufidou F, Constantinides VC, et al. Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review. Diagnostics (Basel). 2022;12(12):2976. https:\/\/doi.org\/10.3390\/diagnostics12122976. Published 2022 Nov 28.","journal-title":"Diagnostics (Basel)"},{"issue":"15","key":"784_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.0b013e31828c2fda","volume":"80","author":"J Jeppsson","year":"2013","unstructured":"Jeppsson J, Zetterberg A, Blennow H, Wikkels\u00f8 K. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013;80(15):1385\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fda.","journal-title":"Neurology"},{"issue":"3","key":"784_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JAD-180059","volume":"63","author":"C Akiba","year":"2018","unstructured":"Akiba C, Nakajima M, Miyajima M, et al. Change of Amyloid-\u03b2 1\u201342 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus. J Alzheimers Dis. 2018;63(3):989\u20131002. https:\/\/doi.org\/10.3233\/JAD-180059.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"784_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"3","key":"784_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"12","key":"784_CR11","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;12(12):e12921. https:\/\/doi.org\/10.15252\/emmm.202012921.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"784_CR12","doi-asserted-by":"publisher","first-page":"e66381","DOI":"10.1371\/journal.pone.0066381","volume":"8","author":"M H\u00f6ltt\u00e4","year":"2013","unstructured":"H\u00f6ltt\u00e4 M, Hansson O, Andreasson U, et al. Evaluating amyloid-\u03b2 oligomers in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. PLoS ONE. 2013;8(6):e66381. https:\/\/doi.org\/10.1371\/journal.pone.0066381. Published 2013 Jun 14.","journal-title":"PLoS ONE"},{"issue":"1","key":"784_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JAD-210226","volume":"83","author":"K Kawamura","year":"2021","unstructured":"Kawamura K, Miyajima M, Nakajima M, et al. Cerebrospinal Fluid Amyloid-\u03b2 Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus. J Alzheimers Dis. 2021;83(1):179\u201390. https:\/\/doi.org\/10.3233\/JAD-210226.","journal-title":"J Alzheimers Dis"},{"key":"784_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2176\/nmc.48.s1","volume":"48","author":"M Ishikawa","year":"2008","unstructured":"Ishikawa M, Hashimoto M, Kuwana N, et al. Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo). 2008;48:S1\u201323. https:\/\/doi.org\/10.2176\/nmc.48.s1.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"784_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"784_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000111149","volume":"25","author":"Y Kubo","year":"2008","unstructured":"Kubo Y, Kazui H, Yoshida T, et al. Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord. 2008;25(1):37\u201345. https:\/\/doi.org\/10.1159\/000111149.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"784_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/JAD-180557","volume":"66","author":"M Nakajima","year":"2018","unstructured":"Nakajima M, Miyajima M, Ogino I, et al. Preoperative phosphorylated tau concentration in the cerebrospinal fluid can predict cognitive function three years after shunt surgery in patients with idiopathic normal pressure hydrocephalus. J Alzheimers Dis. 2018;66(1):319\u201331. https:\/\/doi.org\/10.3233\/JAD-180557.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"784_CR18","doi-asserted-by":"publisher","first-page":"e0119973","DOI":"10.1371\/journal.pone.0119973","volume":"10","author":"M Moriya","year":"2015","unstructured":"Moriya M, Miyajima M, Nakajima M, Ogino I, Arai H. Impact of cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus on the amyloid cascade. PLoS ONE. 2015;10(3):e0119973. https:\/\/doi.org\/10.1371\/journal.pone.0119973. Published 2015 Mar 30.","journal-title":"PLoS ONE"},{"issue":"8","key":"784_CR19","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1096\/fj.09-150359","volume":"24","author":"H Fukumoto","year":"2010","unstructured":"Fukumoto H, Tokuda T, Kasai T, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010;24(8):2716\u201326. https:\/\/doi.org\/10.1096\/fj.09-150359.","journal-title":"FASEB J"},{"key":"784_CR20","volume-title":"Human A\u03b2 oligomer (High Molecular) ELISA Kit, BAN50-based","author":"Fujifilm Wako Pure Chemical Corp","year":"2020","unstructured":"Fujifilm Wako Pure Chemical Corp. Human A\u03b2 oligomer (High Molecular) ELISA Kit, BAN50-based. Osaka: Wako; 2020."},{"issue":"2","key":"784_CR21","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1002\/dad2.12589","volume":"16","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke L, Rehn F, Kraemer-Schulien V, et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alzheimers Dement (Amst). 2024;16(2):e12589. https:\/\/doi.org\/10.1002\/dad2.12589. Published 2024 Apr 25.","journal-title":"Alzheimers Dement (Amst)"},{"key":"784_CR22","unstructured":"U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer\u2019s disease (Lumipulse G pTau217\/\u03b2-Amyloid 1\u201342 plasma ratio). Press announcement. 2025 May 16. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"issue":"8","key":"784_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","volume":"75","author":"RO Roberts","year":"2018","unstructured":"Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurol. 2018;75(8):970\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0629.","journal-title":"JAMA Neurol"},{"issue":"22","key":"784_CR24","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.3390\/ijms242216288","volume":"24","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE, Al-Ghraiybah NF, Odum J, Shunnarah JG, Austin N, Kaddoumi A. Blood-Brain Barrier Breakdown in Alzheimer\u2019s Disease: Mechanisms and Targeted Strategies. Int J Mol Sci. 2023;24(22):16288. https:\/\/doi.org\/10.3390\/ijms242216288. Published 2023 Nov 14.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"784_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/187152709787601867","volume":"8","author":"R Deane","year":"2009","unstructured":"Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets. 2009;8(1):16\u201330. https:\/\/doi.org\/10.2174\/187152709787601867.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"784_CR26","doi-asserted-by":"publisher","unstructured":"Menendez-Gonzalez M, Padilla-Zambrano HS, Alvarez G, Capetillo-Zarate E, Tomas-Zapico C, Costa A. Targeting beta-amyloid at the CSF: a new therapeutic strategy in Alzheimer\u2019s disease. Front Aging Neurosci. 2018;10:100. Published 2018 Apr 16. https:\/\/doi.org\/10.3389\/fnagi.2018.00100.","DOI":"10.3389\/fnagi.2018.00100"},{"issue":"2","key":"784_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1073858410381532","volume":"17","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Lee DH. Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist. 2011;17(2):163\u201373. https:\/\/doi.org\/10.1177\/1073858410381532.","journal-title":"Neuroscientist"},{"issue":"1","key":"784_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","volume":"213","author":"M Chen","year":"1995","unstructured":"Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 1995;213(1):96\u2013103. https:\/\/doi.org\/10.1006\/bbrc.1995.2103.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"784_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12987-022-00309-z","volume":"19","author":"H Lukkarinen","year":"2022","unstructured":"Lukkarinen H, Jeppsson A, Wikkels\u00f6 C, et al. Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. Fluids Barriers CNS. 2022;19(1):11. https:\/\/doi.org\/10.1186\/s12987-022-00309-z. Published 2022 Feb 5.","journal-title":"Fluids Barriers CNS"},{"issue":"7","key":"784_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00701-022-05154-5","volume":"164","author":"SG Thavarajasingam","year":"2022","unstructured":"Thavarajasingam SG, El-Khatib M, Vemulapalli KV, et al. Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis. Acta Neurochir (Wien). 2022;164(7):1719\u201346. https:\/\/doi.org\/10.1007\/s00701-022-05154-5.","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"784_CR31","doi-asserted-by":"publisher","first-page":"e91974","DOI":"10.1371\/journal.pone.0091974","volume":"9","author":"OT Pyykk\u00f6","year":"2014","unstructured":"Pyykk\u00f6 OT, Lumela M, Rummukainen J, et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS ONE. 2014;9(3):e91974. https:\/\/doi.org\/10.1371\/journal.pone.0091974. Published 2014 Mar 17.","journal-title":"PLoS ONE"},{"issue":"2","key":"784_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","volume":"85","author":"A Montagne","year":"2015","unstructured":"Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296\u2013302. https:\/\/doi.org\/10.1016\/j.neuron.2014.12.032.","journal-title":"Neuron"},{"issue":"7","key":"784_CR33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/biomedicines10071509","volume":"10","author":"TG Schreiner","year":"2022","unstructured":"Schreiner TG, Men\u00e9ndez-Gonz\u00e1lez M, Popescu BO. The Cerebrospinal Fluid Sink Therapeutic Strategy in Alzheimer\u2019s Disease-From Theory to Design of Applied Systems. Biomedicines. 2022;10(7):1509. https:\/\/doi.org\/10.3390\/biomedicines10071509. Published 2022 Jun 25.","journal-title":"Biomedicines"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-026-00784-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00784-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:26:33Z","timestamp":1781637993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-026-00784-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1186\/s12987-026-00784-8","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Juntendo University (approval No. H17-0022, H18-02998, E25-0339). The requirement for written informed consent was waived due to the retrospective design and use of de\u2011identified data. Research information was disclosed publicly and participants were given the opportunity to opt out according to institutional policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual person\u2019s data are presented that would require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}